CLINICAL TRIALS PROFILE FOR REVLIMID
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Revlimid
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00974233 ↗ | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | Completed | Celgene Corporation | Phase 2 | 2009-10-01 | The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms. |
| New Combination | NCT00974233 ↗ | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | Completed | University of Wisconsin, Madison | Phase 2 | 2009-10-01 | The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Revlimid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00056160 ↗ | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | Completed | Celgene | Phase 3 | 2003-01-01 | Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase. |
| NCT00056160 ↗ | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | Completed | Celgene Corporation | Phase 3 | 2003-01-01 | Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase. |
| NCT00067743 ↗ | A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) | Completed | Celgene Corporation | Phase 2 | 2003-08-01 | This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks) |
| NCT00087672 ↗ | A Phase II Study of CC-5013 in Myelofibrosis | Completed | Celgene Corporation | Phase 2 | 2004-07-01 | The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied. |
| NCT00087672 ↗ | A Phase II Study of CC-5013 in Myelofibrosis | Completed | M.D. Anderson Cancer Center | Phase 2 | 2004-07-01 | The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied. |
| NCT00093028 ↗ | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | Completed | University of Arkansas | Phase 3 | 2004-01-01 | The purpose of this study is - to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), - to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, - to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies). |
| NCT00098475 ↗ | Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma | Active, not recruiting | National Cancer Institute (NCI) | Phase 3 | 2004-10-26 | This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Revlimid
Condition Name
Clinical Trial Locations for Revlimid
Trials by Country
Clinical Trial Progress for Revlimid
Clinical Trial Phase
Clinical Trial Sponsors for Revlimid
Sponsor Name
